These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 1411618)

  • 41. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
    Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
    Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-].
    Kuhn W; Schmalfeldt B; Dose J; Pache L; Ulm K; Freitag K; Jänicke F; Graeff H
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):105-10. PubMed ID: 8647360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.
    Lund B; Hansen M; Hansen OP; Hansen HH
    J Clin Oncol; 1990 Jul; 8(7):1226-30. PubMed ID: 2113570
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
    Waterhouse DM; Reynolds RK; Natale RB
    Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [CDDP-ACR treatment in patients with recurrent ovarian cancer with prior chemotherapy containing CDDP--a preliminary study of a 14-day continuous infusion of CDDP with ACR].
    Chen JT; Hirai Y; Nakayama K; Shimizu Y; Yokosuka K; Teshima H; Hamada T; Fujimoto I; Yamauchi K; Hasumi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1565-70. PubMed ID: 2584809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
    Kushner BH; Modak S; Kramer K; Basu EM; Roberts SS; Cheung NK
    Cancer; 2013 Feb; 119(3):665-71. PubMed ID: 22951749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
    Smith IE; Perren TJ; Ashley SA; Woodiwiss J; Forgeson GV; Yarnold JR; Ford HT
    J Clin Oncol; 1990 May; 8(5):899-905. PubMed ID: 2159056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
    J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer.
    Fanning J; Hilgers RD; Hutson E
    Am J Clin Oncol; 1994 Aug; 17(4):335-7. PubMed ID: 8048396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
    Nishida T; Nagasue N
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 May; 40(5):635-9. PubMed ID: 3133435
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of recurrent ovarian cancer].
    Kudo R; Sagae S
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1991-7. PubMed ID: 1358032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
    Nichols CR; Tricot G; Williams SD; van Besien K; Loehrer PJ; Roth BJ; Akard L; Hoffman R; Goulet R; Wolff SN
    J Clin Oncol; 1989 Jul; 7(7):932-9. PubMed ID: 2544687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
    Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T
    Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
    Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
    J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.